Bristol-Myers Squibb

Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis (2023) Fitzgerald O, Behrens F, Barton A, Bertheusen H, Boutouyrie-Dumont B, Coates L, Davies O, et al. Journal article, Review article Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study (2022) Wong SW, Bar N, Paris L, Hofmeister CC, Hansson M, Santoro A, Mateos MV, et al. Conference contribution High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study (2021) Behrens F, Rech J, Thaci D, Zinke S, Rothnie KJ, (Oefner) Daamen C, Leipe J Journal article Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma (2021) Da Via MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, et al. Journal article Idecabtagene vicleucel in relapsed and refractory multiple myeloma (2021) Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, et al. Journal article Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer (2021) Konecny GE, Hendrickson AE, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, et al. Journal article Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study (2019) Peichl P, Alten R, Galeazzi M, Lorenz HM, Nüsslein H, Navarro F, Elbez Y, et al. Journal article Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (Clinical Rheumatology, (2019), 38, 5, (1413-1424), 10.1007/s10067-019-04449-w) (2019) Alten R, Mariette X, Lorenz HM, Nüsslein H, Galeazzi M, Navarro F, Chartier M, et al. Journal article, Erratum Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (2019) Alten R, Mariette X, Lorenz HM, Nüsslein H, Galeazzi M, Navarro F, Chartier M, et al. Journal article Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries (2019) Alten R, Feist E, Lorenz HM, Nüsslein H, Voll RE, Chartier M, Elbez Y, Rauch C Journal article